Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers

A Phase 1a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Oral MORF-057 in Healthy Subjects

Phase 1a randomized, double-blind, placebo-controlled study to evaluate single and multiple ascending doses of MORF-057 in healthy subjects.

Inclusion Criteria:

• Healthy male and female subjects between 18 to 65 years old with a body mass index between 18 and 32 kg/m2
• Determined to be medically healthy by the Investigator.
• Use of acceptable methods of contraceptives.
• Ability to provide written informed consent and to understand and comply with the requirements of the study.

Exclusion Criteria:

• History of any malignancy, except basal or squamous cell carcinoma of the skin that resolved or in remission prior to Screening.
• Abnormal laboratory values at Screening.
• Any clinically significant major diseases.
• Female who is pregnant or breastfeeding, or planning to become pregnant during the course of the study.
• Unwilling or unable to comply with the requirements of the protocol.